Posts by Mourabit Halima

Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France. Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation). He is MD and also holds a PhD in virology. His fields of research include chronic liver diseases, translational medicine and treatment of HBV, HCV and HDV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. He coordinated major international clinical trials on HCV, HBV and HDV infections. He has published more than 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60). He has been selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and for his leadership in Hepatology in 2019 from the Czech Hepatology Society.

Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress Tom Hemming Karlsen (MD, PhD) is a clinical specialist in internal medicine and gastroenterology working in Oslo, Norway. Dr. Karlsen graduated from medical school at the University of Bergen in 1997. In 2012 he was appointed professor of gastroenterology at the University of Bergen and in 2014 he was appointed full professor of internal medicine at the University of Oslo. Within the Oslo University Hospital he is Research Head of the Division of Surgery, Inflammatory medicine and Transplantation, and is also leader of the Norwegian PSC research center at the Department of Transplantation Medicine and Research Institute of Internal Medicine. Clinically, he works as a senior consultant within transplant hepatology at the Section of Gastroenterology at the Department of Transplantation Medicine

Early treatment is the key to improving the survival rate of liver cancer patients. At the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Fabio Piscaglia from the University of Bologna, Italy, presented the latest developments in the treatment of early-stage hepatocellular carcinoma (HCC) in a special session titled "Treatment of early stage HCC in 2023." Hepatology Digest had the privilege of inviting Professor Fabio Piscaglia to share insights into HCC treatment strategies, strategies for preventing HCC recurrence, and the current status and prospects of emerging technologies for tumour molecular characterization.